Latest Articles

  • Company Logo for PFE

    Should You Buy Pfizer Stock After An Upbeat Q2?

    Pfizer stock   (NYSE: PFE) reported its Q2 results last week, with revenue and earnings comfortably above ours and the street estimates. However, PFE stock has seen a fall of around 5% in a week as the company didn’t raise its full-year ou...


  • Company Logo for PFE

    Should You Buy Pfizer Stock Ahead of Its Q2 Results?

    Pfizer (NYSE: PFE) is scheduled to report its Q2 2022 results on Thursday, July 28, and we expect it to post revenue and earnings well above the consensus estimates. Its Covid-19 vaccine and the antiviral pill will continue to drive revenue growt...


  • Company Logo for PFE

    Should You Buy, Sell, Or Hold Pfizer Stock At $52?

    After an 8% fall year-to-date, at the current levels, we believe Pfizer stock (NYSE: PFE) has some room for growth. PFE stock fell from $57 in early January to $52 now. The YTD -8% return for PFE marks an outperformance with -19% returns for th...


  • Company Logo for FDX

    Here’s A Better Pick Over FedEx Stock

    We think that  Pfizer stock (NYSE: PFE) currently is a better pick compared to FedEx stock   (NYSE: FDX), despite it being the more expensive of the two, trading at 3.3x trailing revenues compared to 0.6x for FedEx. The gap in the valuation of ...


  • Company Logo for PFE

    Company Of The Day: Pfizer

    What? Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion. Why? Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisiti...


  • Company Logo for PFE

    What To Expect From Pfizer’s Q1?

    Pfizer (NYSE: PFE) is scheduled to report its Q1 2022 results on Tuesday, May 3. We expect the company to likely post revenue and earnings below the consensus estimates. The revenue from its Covid-19 vaccine and antiviral pill sales may be lower ...


  • Company Logo for PFE

    Company Of The Day: Pfizer

    What? A recently published study from Israel on booster shots of Pfizer (NYSE:PFE) and its partner BioNTech’s Covid-19 vaccine indicates that a fourth dose of the vaccine (second booster) lowered the risk of severe disease in the elderly, ...


  • Company Logo for PFE

    Will Pfizer Stock See Higher Levels After A 10% Rise In A Month?

    The stock price of Pfizer (NYSE: PFE) has seen a rise of 10% over the last month, while it is down 6% YTD. The increase over the previous month can partly be attributed to Pfizer’s acquisition of Arena Pharmaceuticals for $6.7 billion. Th...


  • Company Logo for PFE

    Company Of The Day: Pfizer

    What? Pfizer (NYSE:PFE) said that the U.S. FDA granted the company’s vaccine candidate targeted at respiratory syncytial virus PF-06928316 (RSVpreF) a Breakthrough Therapy designation. Why? The Breakthrough Therapy designation is meant ...


  • Company Logo for PFE

    Are Covid-19 Treatment Stocks A Buy As Global Infections Rise Again?

    Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus – has declined by about 2% year-to-date, outperforming the S&P 500 which has declined by...


  • Company Logo for PFE

    What’s Next For Pfizer Stock After A 10% Fall In A Month?

    The stock price of Pfizer (NYSE: PFE) has seen a fall of 10% over the last month, while it is up 4% in a week. The decline over the previous month can be attributed to Pfizer’s underwhelming guidance for its Covid-19 vaccine and treatment...


  • Company Logo for PFE

    Does The Current Dip In Pfizer Stock Offer A Buying Opportunity?

    [Updated: Feb 10, 2022] Pfizer Q4 Earnings Update The stock price of Pfizer (NYSE: PFE) has seen a fall of 8% over the last month, while it is down over 3% in a week. The recent decline can be attributed to the company’s mixed Q4 results...


  • Company Logo for PFE

    Company Of The Day: Pfizer

    What? Pfizer (NYSE:PFE) posted better than expected Q4 2021 earnings, with adjusted EPS coming in at $1.08, up from about $0.43 in Q4 2020. However, revenue growth, which came in at 104% year-over-year, missed estimates. Why? Growth was drive...


  • Company Logo for PFE

    Forecast Of The Day: Pfizer’s Oncology Revenue

    What? Pfizer’s (NYSE:PFE) Oncology Revenue, which includes revenues from Sutent, Xalkori, Inlyta, Ibrance, and other productions, rose from around $9 billion in 2019 to about $11 billion in 2020. We expect the metric to rise to around $12...


Next ▶